MDM2 amplification
|
Liposarcoma
|
MDM2 amplification
|
Liposarcoma
|
APG-115 Sensitive: C2 – Inclusion Criteria
|
APG-115 Sensitive: C2 – Inclusion Criteria
|
MDM2 amplification
|
Solid Tumor
|
MDM2 amplification
|
Solid Tumor
|
RAIN-32 Sensitive: C2 – Inclusion Criteria
|
RAIN-32 Sensitive: C2 – Inclusion Criteria
|
MDM2 amplification
|
Liposarcoma
|
MDM2 amplification
|
Liposarcoma
|
RAIN-32 Sensitive: C2 – Inclusion Criteria
|
RAIN-32 Sensitive: C2 – Inclusion Criteria
|
MDM2 amplification
|
Liposarcoma
|
MDM2 amplification
|
Liposarcoma
|
BI 907828 Sensitive: C2 – Inclusion Criteria
|
BI 907828 Sensitive: C2 – Inclusion Criteria
|
MDM2 amplification
|
Mucosal Melanoma
|
MDM2 amplification
|
Mucosal Melanoma
|
ipilimumab Resistant: C3 – Early Trials
|
ipilimumab Resistant: C3 – Early Trials
|
MDM2 amplification
|
Mucosal Melanoma
|
MDM2 amplification
|
Mucosal Melanoma
|
nivolumab + ipilimumab Resistant: C3 – Early Trials
|
nivolumab + ipilimumab Resistant: C3 – Early Trials
|
MDM2 amplification
|
Mucosal Melanoma
|
MDM2 amplification
|
Mucosal Melanoma
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
MDM2 amplification
|
Mucosal Melanoma
|
MDM2 amplification
|
Mucosal Melanoma
|
pembrolizumab Resistant: C3 – Early Trials
|
pembrolizumab Resistant: C3 – Early Trials
|
MDM2 amplification
|
Gastric Adenocarcinoma
|
MDM2 amplification
|
Gastric Adenocarcinoma
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
MDM2 amplification
|
Sarcoma
|
MDM2 amplification
|
Sarcoma
|
RAIN-32 Sensitive: C3 – Early Trials
|
RAIN-32 Sensitive: C3 – Early Trials
|
MDM2 amplification
|
Diffuse Large B Cell Lymphoma
|
MDM2 amplification
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
|
R-CHOP Resistant: C3 – Early Trials
|
MDM2 amplification
|
Solid Tumor
|
MDM2 amplification
|
Solid Tumor
|
BI 907828 + BI 754091 Sensitive: C3 – Early Trials
|
BI 907828 + BI 754091 Sensitive: C3 – Early Trials
|
MDM2 amplification
|
Triple Negative Breast Cancer
|
MDM2 amplification
|
Triple Negative Breast Cancer
|
pembrolizumab Resistant: C4 – Case Studies
|
pembrolizumab Resistant: C4 – Case Studies
|